Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aethlon Medical has initiated a research collaboration with ImQuest Biosciences, an infectious disease research organization, to study the in vitro effectiveness of the Aethlon hemopurifier in clearing the human immunodeficiency virus from blood.
Subscribe to our email newsletter
The studies will document the rate at which the Aethlon hemopurifier captures infectious forms of human immunodeficiency virus (HIV), including multi-drug resistant strains of the virus. The studies will also identify the capture rate of gp120, a toxin shed from the surface of HIV, which causes apoptosis (programmed cell death) of immune cells.
The goal of the studies will be to reinforce and expand upon HIV data previously obtained by Aethlon researchers. In HIV care, the hemopurifier is targeted to fill treatment voids of concern to all HIV-infected individuals and to act as an adjunct therapy to extend and enhance the benefit of antiviral drug regimens by inhibiting the proliferation of drug resistant HIV and immunosuppressive toxins.